Slate Bio is an immunotherapeutics development company that develops therapeutic solutions for autoimmune diseases.
Slate Bio has raised $2.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2023.
Slate Bio's investors include Epidarex Capital, Virginia Venture Partners, PharmaDirections, UVA Licensing & Ventures Group, VTC Seed Fund.
Slate Bio is headquartered in Charlottesville, United States.
Slate Bio is an immunotherapeutics development company that develops therapeutic solutions for autoimmune diseases.
Slate Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Slate Bio — Funding & Investors." VCBacked, January 17, 2023, https://www.vcbacked.co/company/slate-bio. Accessed September 30, 2026.
VCBacked. (2023). Slate Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/slate-bio
{{cite web |title=Slate Bio — Funding & Investors |url=https://www.vcbacked.co/company/slate-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated